Vraylar Cost Information
The wholesale acquisition cost for Vraylar (cariprazine) is not provided in the available evidence, as none of the retrieved studies or guidelines contain pricing information for this medication.
What We Know About Vraylar
While cost data is unavailable in the provided evidence, the following clinical information about Vraylar may be relevant:
FDA-Approved Indications
- Vraylar is approved in the United States for treating schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, and depressive episodes associated with bipolar I disorder 1, 2.
Dosing Information
- For schizophrenia and bipolar mania, effective doses range from 1.5 mg to 9.0 mg daily, with most studies showing efficacy at 1.5,3.0,4.5, and 6.0 mg daily doses 3, 4.
- For bipolar depression, approved doses are 1.5 mg and 3.0 mg daily 2.
- The medication requires slow titration due to its long half-life, with the active metabolite didesmethyl-cariprazine (DDCAR) having a half-life of 1-3 weeks 2, 5.
Unique Pharmacology
- Cariprazine is a dopamine D3-preferring D3/D2 receptor partial agonist with 10-fold higher affinity for D3 receptors compared to D2 receptors, distinguishing it from other antipsychotics like aripiprazole 1, 3.
How to Obtain Current Pricing
To determine actual costs for your patient, you should:
- Contact local pharmacies directly for current retail pricing
- Check the manufacturer's website for patient assistance programs
- Verify insurance formulary coverage and copay amounts
- Consider using prescription discount programs or cards
The absence of pricing data in clinical guidelines and research literature reflects that medication costs vary significantly by insurance coverage, pharmacy, geographic location, and available discount programs, making real-time verification essential for accurate patient counseling.